Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
Explore this paper's citation graph
Summary
The results, the benefits and new challenges that the combination of chemotherapy and IO can bring to patients with metastatic urothelial carcinoma are reviewed.
- Type
- article
- Published
- 2020-02-12
- Cited by
- 3
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W3005725522
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:213130782
Keywords
Metastatic Urothelial Carcinoma, Chemotherapy, Medicine, Urothelial cancer, Immunotherapy
References
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
- Mutational heterogeneity in cancer and the search for new cancer genes
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
- Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
- International variations in bladder cancer incidence and mortality.
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
- Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
- Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy
- Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
- IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
- First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
- Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for metastatic NSCLC?
- Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
- First-line Immunotherapy in Metastatic Urothelial Carcinoma.
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Cited by
- Computational modelling of modern cancer immunotherapy
- N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer
- Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward
Related papers
- 51 Epigenetic alterations associated with neo-adjuvant chemotherapy resistance in bladder cancer
- [Immunotherapy in advanced urothelial cancer].
- First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
- Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
- Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.
- PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
- BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States